OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

OXB is likely to go up tomorrow given its chart at the moment

Correct hlyeo98

UP 2.5% so far.

1st resistance @ 21p. If this is breached then next resistance 26-27p. May well test that 21p level later today.

DSTOREY9916 - Perhaps as the pessimists at this party we will be pleasantly surprised. Let's hope so.

queen 1, hope so for sake of those who are suffering with cancer, parkinson's and so on..

Resistance at 21 not breached. May well see a retrenchment early next week but this will only be a breather and expect sp too have an upward trend in anticipation of RNS(s!?). Into a nice higher/low's pattern. However would expect sp too slide if no positive newsflow forth coming in near future given expectations. IMHO.

I agree - have a good weekend and stay lucky.

FINANCIAL TIMES today


Oxford Biomedica
Published: October 9 2004 03:00 | Last updated: October 9 2004 03:00

Shares in Oxford Biomedica rose 21 per cent to 20p after Panmure Gordon initiated coverage of the biotech company with a "buy" recommendation and a target price of 50p. The broker said: "We like Oxford Biomedica because uniquely in the UK biotech sector it has a large number of products at a relatively late stage of R&D. This provides a security net against 'all the eggs in one basket' slip-ups". The company is working on two cancer drugs and several neurotherapy treatments. Panmure expects Oxford Biomedica to sign at least one and up to three partnership deals next year.

Great post Janus. Surely if it signs 3 partnership deals next year 50p will be the very least we could hope for.

UP again so far today.

First obstacle is to get through the 21p barrier - followed by some good news - I am off for a couple of weeks and will be watching daily (from a sun bed with an expensive newspaper)how you all get on in my absence

Enjoy your basting Oakaooles142!

12/10/04 10:37 Director Shareholding RNS


Oxford Biomedica PLC
12 October 2004


Oxford BioMedica plc ('the Company')

Directors' Interest in Options over 1p Ordinary Shares

12 October 2004

The Company announced that today it has granted additional share options to
certain Directors, under the Oxford BioMedica 1996 (No.1) Share Option Scheme.
The exercise price for each of the options is 20.5 pence per share. There was no
payment in respect of the grant of these options. The new options may be
exercised between 12 October 2007 and 12 October 2011, but only if at the time
of exercise, or for at least 12 months in the three years before exercise, the
percentage increase in Oxford BioMedica's Total Shareholder Return exceeds the
percentage increase in the FTSE TechMark Mediscience index since the date of
grant of the option. The new options granted to directors are: Professor Alan
Kingsman 190,000 options, Professor Susan Kingsman 155,000 options, Peter Nolan
140,000 options and Andrew Wood 175,000 options.

Following the grant of these options, the interests of these directors in
options over 1p ordinary shares of the Company are: Professor Alan Kingsman
370,000 options, Professor Susan Kingsman 305,000 options, Peter Nolan 1,111,229
options and Andrew Wood 1,505,036 options.

Andrew Wood
Company Secretary, Oxford BioMedica plc
Tel. 01865 783000
12 October 2004

Small rise yesterday, looks like more coming today.

so its maintained 21p for a couple of days, where's the good news then ???

Cancer News Article



New Vaccine for Treatment of Colorectal Cancer Shows Promise in Phase II Trial
The results of a recent phase II study conducted in Europe indicate that TroVax is promising for the treatment of stage IV colorectal cancer.

Colorectal cancer is the second leading cause of cancer related deaths in the United States. Colorectal cancer is a malignancy that involves both the large intestines (colon) and a distal portion of the colon known as the rectum. Current treatment options for colorectal cancer include surgery, radiation and chemotherapy.

Another type of cancer treatment is biologic therapy, which uses the bodys own immune system to fight cancer. The immune system is the bodys natural defense against foreign substances and abnormal growth. It is a complex system that relies on many different substances and steps to effectively defend the body against foreign invaders, such as viruses and bacteria, and abnormal growth, such as cancer. Biological therapies are substances that can interfere in any number of these steps to help the immune system recognize and kill cancer cells. Biological therapies are produced in a laboratory and may be replications of naturally occurring substances or synthetic substances.

TroVax is a new drug developed to stimulate the patients immune system to mount an antibody response against the 5T4 antigen associated with colorectal cancer. The trial conducted in England is not yet complete; however, interim analysis has shown that TroVax is safe when given in addition to standard chemotherapy and patients are able to mount an immune response to the antigen. TroVax would be the first type of immunotherapy developed for the treatment of colon cancer.

The recently published report is based on 13 patients who received 4 TroVax injections and at least 8 cycles of chemotherapy. Of these 13 patients, 11 (85%) mounted antibody responses to the 5T4 antigen. Further analysis will be published in 2005 when all patients will have completed 6 doses of TroVax and 12 cycles of chemotherapy.

Two additional trials are also being analyzed comparing TroVax given with fluorouracil, leucovorin and irinotecan chemotherapy (IFL), or TroVax given with fluorouracil, leucovorin and oxaliplatin chemotherapy. (FOLFOX). At this time, 9 of the10 patients who received IFL and TroVax have mounted an immune response to the 5T4 antigen. In the group receiving FOLFOX with TroVax, only 3 of the 17 patients are currently ready for interim analysis and of these, 2 have mounted an anti-tumor response (67%).

Further trials of TroVax are ongoing and researchers are confident that TroVax will have a role in the treatment of colorectal cancer.

Reference: Pharmalive.com. Oxford Biomedica Announces Positive Interim Phase II Results with Trovax in Colorectal Cancer. http://www.pharmalive.com.

1998- 2004 CancerConsultants.com All Rights Reserved.

These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.

Thanks The Gull,

Where did you get that from?

What was the internet address?

Apple

Typed TroVax into google search, below is one of the links that came up.

I just copy pasted the article - not sure when it was written?

imo - seems the industry sentiment is quite positive.

http://patient.cancerconsultants.com/news.aspx?id=31375

AICR.

Regards

Gull

Thanks

Sold half,

It looks like we'll drift down again until the next news.